Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: changedmyname who wrote (83754)	3/8/2000 12:29:00 PM
From: jopawa	Read Replies (1) \| Respond to of 108040

VPHM going to blow, small float could easily blow this one to 120, look at PDLI to see a mirror of what will happen here, 120 today on the CNBC pump, higher later this week

To: changedmyname who wrote (83754)	3/8/2000 12:33:00 PM
From: jopawa	Respond to of 108040

VPHM biz summary fits the cnbc pump to perfection: Business Summary ViroPharma Incorporated is a development stage pharmaceutical company committed to the commercialization, development and discovery of new antiviral medicines. Its current drug development and discovery activities are focused on a number of ribonucleic acid (RNA) virus diseases, including viral meningitis, viral respiratory infection, the common cold, respiratory syncytial virus pneumonia and hepatitis C. ViroPharma's most advanced product candidate, pleconaril, is being developed for the treatment of common RNA virus diseases. ViroPharma has completed a Phase II challenge study in viral respiratory infection (VRI) with pleconaril, in which all evaluated disease measures were significantly reduced in treated subjects, along with another Phase II clinical trial for viral meningitis which demonstrated that pleconaril significantly reduced disease duration.